Clinical trials: Ceftazidime Treatment
Gram Negative Infection, Antimicrobial Resistance (AMR)
PK/PD Analysis of Ceftazidime/Avibactam or Cefiderocol With or Without Fosfomycin for the Treatment of Difficult To-treat Gram-negative Infections
A multicenter, national, prospective, observational pharmacological study of patients with difficult-to-treat Gram-negative infections treated with ceftazidime/avibactam (CAZ/AVI) or cefiderocol (CEF) monotherapy or combination…
- Trial name
- PACCOF (NCT06651047)
- Where
- 11 sites in Italy
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Bologna
Ceftazidime-avibactam
Individualized Precision Therapy With Ceftazidime and Avibactam Guided by PK/PD in Geriatric Populations
Ceftazidime-avibactam is a β-lactam/β-lactamase inhibitor combination treatment which has been developed to address infections caused by ESBL-, AmpC- and serine carbapenemase-producing Gram-negative bacteria.
- Trial name
- NCT07494981
- Testing
- liquid chromatography-tandem mass spectrometry
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Chinese PLA General Hospital
Pharmacokinetics, Open Label
A Study to Investigate the Effect of Administration of Ceftazidime-avibactam (CAZ-AVI) and Ceftaroline Fosamil -Avibactam (CXL) on the Intestinal Flora of Healthy Volunteers
The purpose of this study is to investigate the effect of administration of CAZ-AVI and CXL on the intestinal flora of male and female healthy volunteers after multiple administrations over 7 days.
- Conditions
- Pharmacokinetics, Open Label, CAZ-AVI, CXL
- Trial name
- NCT01789528
- Testing
- CAZ-AVI, CXL
- Where
- Sweden
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Pfizer